Pediatrix officer plans sale of 21,335 shares

Officer Mary Ann E. Moore filed a Rule 144 notice to sell Pediatrix Medical Group common shares previously received from vested stock awards.

Rhea-AI Filing Summary

Pediatrix Medical Group, Inc. (MD) received a Rule 144 notice from officer Mary Ann E. Moore covering an intended sale of 21,335 shares of common stock through Merrill Lynch on the NYSE. The filing states an aggregate market value of $572,619.71 for these shares and notes 81,253,271 shares outstanding as of September 11, 2026. The shares relate to multiple vested stock awards and follow a prior sale of 9,260 shares in the last three months.

Key Figures

Shares to be sold under Rule 144: 21,335 shares Aggregate market value of shares to be sold: $572,619.71 Shares outstanding: 81,253,271 shares +3 more

6 metrics

Shares to be sold under Rule 144 21,335 shares Common stock planned for sale by Mary Ann E. Moore

Aggregate market value of shares to be sold $572,619.71 Value reported for 21,335 shares of common stock

Shares outstanding 81,253,271 shares Common shares outstanding as of September 11, 2026

Recent shares sold 9,260 shares Common shares sold on August 14, 2026 by Mary Ann E. Moore

Proceeds from recent sale $246,365.53 Sale of 9,260 shares on August 14, 2026

Largest single vesting lot 10,371 shares Common stock vested on June 1, 2025 as a stock award

Key Terms

Rule 144, Vesting of a Stock Award, Compensatory Payment

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Vesting of a Stock Award financial

"Common | 06/01/2025 | Vesting of a Stock Award | Pediatrix Medical Group, Inc."

Compensatory Payment financial

"10371 | 06/01/2025 | Compensatory Payment"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing disclose for Pediatrix Medical Group (MD)?

It discloses that officer Mary Ann E. Moore filed a Rule 144 notice to sell up to 21,335 shares of Pediatrix Medical Group common stock through Merrill Lynch on the NYSE, with an aggregate market value reported as $572,619.71.

How many Pediatrix Medical Group (MD) shares are covered by this Rule 144 notice?

The notice covers up to 21,335 shares of Pediatrix Medical Group common stock. These shares are to be sold for the account of officer Mary Ann E. Moore and are listed in the securities information section of the filing.

What market value is associated with the Pediatrix Medical Group (MD) shares to be sold?

The filing reports an aggregate market value of $572,619.71 for the 21,335 shares of Pediatrix Medical Group common stock covered by the Rule 144 notice submitted by officer Mary Ann E. Moore.

How many Pediatrix Medical Group (MD) shares were outstanding as of the date in the filing?

The filing states that 81,253,271 shares of Pediatrix Medical Group common stock were outstanding as of September 11, 2026; this is provided as context for the planned sale under Rule 144.

What Pediatrix Medical Group (MD) sales occurred in the last three months for this insider?

The document lists a prior sale by Mary Ann E. Moore of 9,260 shares of Pediatrix Medical Group common stock on August 14, 2026, for proceeds reported as $246,365.53 in the past three months section.

What is the source of the Pediatrix Medical Group (MD) shares being sold?

The filing ties the shares to multiple vesting of a stock award events for Pediatrix Medical Group common stock, each described as a compensatory payment to officer Mary Ann E. Moore on various vesting dates between 2008 and 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/14/2026 - 06:15 PM Accepted by SEC EDGAR 09/14/2026 - 06:14 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001894731
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Pediatrix Medical Group, Inc.
SEC File Number	001-12111
Address of Issuer	1301 Concord Terrace Sunrise FLORIDA 33323
Phone	9543840175
Name of Person for Whose Account the Securities are To Be Sold	Mary Ann E Moore
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 3455 Peachtree Road NE, Suite 1000 Atlanta GA 30326	21335	572619.71	81253271	09/11/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	06/01/2025	Vesting of a Stock Award	Pediatrix Medical Group, Inc.			10371	06/01/2025	Compensatory Payment
Common	03/01/2025	Vesting of a Stock Award	Pediatrix Medical Group, Inc.			3576	03/01/2025	Compensatory Payment
Common	03/01/2022	Vesting of a Stock Award	Pediatrix Medical Group, Inc.			452	03/01/2022	Compensatory Payment
Common	09/01/2020	Vesting of a Stock Award	Pediatrix Medical Group, Inc.			4786	09/01/2020	Compensatory Payment
Common	06/01/2020	Vesting of a Stock Award	Pediatrix Medical Group, Inc.			697	06/01/2020	Compensatory Payment
Common	03/01/2020	Vesting of a Stock Award	Pediatrix Medical Group, Inc.			1293	03/01/2020	Compensatory Payment
Common	12/04/2008	Vesting of a Stock Award	Pediatrix Medical Group, Inc.			160	12/04/2008	Compensatory Payment

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Mary Ann E Moore 1301 Concord Terrace Sunrise FL 33323	Common	08/14/2026	9260	246365.53

144: Remarks and Signature

Remarks
Date of Notice	09/14/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Mary Ann E Moore
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)